On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

Chatbots can get scary if you suspend your disbelief. But MJ Cocking didn’t — and wound up in a relationship that was ...

One woman turns to Reddit after she's been paying to store her boyfriend’s broken car for months. But after watching him ...

A woman shares how her dad expects her to house her cousin during a big move to the UK, but she refuses, sparking a family ...

The Arts Council of Greater Baton Rouge will present His & Hers, a curated evening for couples, at 5:30 p.m. Saturday at the ...

McCracken also adds there’s plenty of livestock that were traveling in these temperatures, with some still on their way out ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

The company will offer a generic version of semaglutide in the country after Novo Nordisk let its patent expire there. Hims & ...

Analysts have provided Laboratory Corp with 8 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $276.5, suggesting a potential 9.69% upside.

Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Hims & Hers (HIMS) stock in focus as the company faces a growing number of lawsuits following Novo Nordisk's (NVO) decision ...

The market for generic GLP-1 weight loss drugs in Canada is set to open up, and Hims & Hers is ready to jump in.  | Novo ...